Company profile
Xenetic Biosciences, Inc.
NASDAQ: XBIO · Healthcare · Biotechnology
#753 of 1,418 Healthcare companies by revenue65th-percentile growth
EA Score
56CFH 49DQ 69GM 61SS 32
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, disclosure history · ↓ workforce scale, Piotroski F
Methodology →Revenue TTM
$3.2M
Rev growth YoY (TTM)
+23.5%
Net income (FY)
-$2.7M
Employees
2
as of 2026-08-23
Market cap
$8.2M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.0M$3.0M2025
Net income-$2.7M-$2.7M2025
Operating income-$2.8M-$2.8M2025
Total assets$8.4M$8.4M2025
Liabilities$968.0k$968.0k2025
Equity$7.4M$7.4M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2020
By product
Royalty Revenue100%
By geography
Not disclosed.
The read
What is Xenetic Biosciences, Inc.’s revenue?
Xenetic Biosciences, Inc. booked $3.0M in FY2025 revenue, growing 19% year over year — faster than most Healthcare companies we track, at a -90.1% net margin.
Peers · Healthcare
Intelligent Bio Solutions Inc.40DNet Medical Xpress Solutions, Inc.——TherapeuticsMD, Inc.60CPeakBirch Commerce Inc.——Protara Therapeutics, Inc.43DOSR Holdings, Inc.34DNeighbors
Middlesex →Key facts
CEOJames F. Parslow
SectorHealthcare
IndustryBiotechnology
HeadquartersFramingham, MA
ExchangeNASDAQ: XBIO
Employees2
IPO date2016-06-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.